Top Industry Leaders in the Cardiopulmonary Disease Diagnostics Treatment Market
Latest Cardiopulmonary Disease Diagnostics and Treatment Companies Updates:
Philips: Introduced the Lumify L15 portable ultrasound system, designed for point-of-care assessment of cardiovascular and respiratory functions, increasing accessibility and early diagnosis.
Abbott: Received FDA approval for the Amplatzer™ Amulet™ Septal Occluder for percutaneous closure of patent foramen ovale (PFO), a potential contributor to stroke, offering a minimally invasive treatment option.
Roche Diagnostics: Developed new blood tests for detecting early-stage heart failure and predicting risk of pulmonary embolism, enabling earlier intervention and improved patient outcomes.
Siemens Healthineers: Acquired Varian Medical Systems, expanding its portfolio of oncology and cardiovascular imaging solutions and strengthening its presence in the healthcare technology landscape.
Johnson & Johnson: Partnered with Verily Life Sciences to develop AI-powered algorithms for diagnosing and managing heart failure, aiming to improve patient outcomes and reduce hospital readmissions.
Novartis: Collaborated with academic institutions and data science companies to develop machine learning models for predicting and preventing acute respiratory distress syndrome (ARDS), a potentially life-threatening complication of various illnesses.
List of Cardiopulmonary Disease Diagnostics and Treatment Key companies in the market:
- Cardinal Health
- Cosmed Medical
- GE Healthcare
- Halma plc
- Hill-Rom Holdings Inc.
- Koninklijke Philips N.V.
- MGC Diagnostics Corporation
- NIHON KOHDEN CORPORATION
- Schiller AG
- Masimo Corporation
